Bioiatriki Healthcare Group enters strategic early Alzheimer's detection partnership with LANGaware

Healthcare provider Bioiatriki Healthcare Group has entered into a strategic partnership with LANGaware, an AI-driven healthcare technology company, towards advancing the early detection and management of neurodegenerative conditions, such as Alzheimer's Disease and Mild Cognitive Impairment (MCI), in Greece and Cyprus.

According to a relevant press release, under this partnership, Bioiatriki, a private healthcare services provider in Greece and Cyprus, is integrating US-based LANGaware's advanced AI-driven platform into its extensive network of over 75 diagnostic centers.

"This platform leverages AI to analyse digital biomarkers from voice and speech, enabling early detection of cognitive and behavioral health conditions with unmatched accuracy. By offering this cutting-edge technology, Bioiatriki empowers patients to detect dementia symptoms at their earliest stages, significantly enhancing patient outcomes and quality of life," the press release noted.

"We are excited to collaborate with Bioiatriki Healthcare Group to bring our innovative technology to more patients," said Dr. Vassiliki Rentoumi, Founder and CEO of LANGaware. "This partnership aligns with our mission to revolutionise early diagnosis and provide effective, accessible solutions for cognitive health management globally."

According to the same announcement, LANGaware's platform provides rapid and accurate results within minutes, requiring only a brief voice recording of the participant describing an image or a daily activity. The system boasts a sensitivity of 90% and a specificity of 85% in detecting Alzheimer's Disease and MCI, significantly reducing the risk of misdiagnosis and unnecessary treatments.

The integration of LANGaware's technology within Bioiatriki's healthcare services is expected to not only improve patient outcomes but also enhance healthcare efficiency by enabling timely interventions and personalised support. This partnership marks a significant step forward in expanding access to advanced diagnostic services and represents a shared commitment to improving cognitive health management, the announcement said.

"LANGaware leverages AI technology to revolutionise cognitive and behavioral health screening. By utilising speech analysis and proprietary voice and speech biomarkers, LANGaware provides early, accurate and objective detection of conditions, enabling more effective treatments, reducing healthcare burdens, and improving overall well-being," it concluded.

Established in 1981, Bioiatriki operates over 75 diagnostic centers, two state-of-the-art hospitals, and various specialised centers, serving more than 3 million patients annually.